INTRODUCTION {#s1}
============

Duchenne muscular dystrophy (DMD) is an X-chromosome-linked disorder that causes progressive muscle atrophy and weakness. It is the most prevalent hereditary muscle disease, occurring in 1 in every 3,600 male births[@r1],[@r2],[@r3]^)^. Also the most common childhood neuromuscular disease, DMD is characterized by a complete loss of dystrophin. Whole-body muscle atrophy and weakness progress over time, and patients are typically unable to walk around 13 years of age[@r4]^)^, with an average life expectancy of roughly 30 years generally limited by respiratory or cardiac failure[@r1], [@r5]^)^.

Although therapeutic strategies such as gene therapy and regenerative medicine have been extensively developed for DMD, definite treatment recommendations for patients with DMD are lacking. Oral prednisolone (PSL) has been associated with improvements in muscle strength and prolongation of independence and is the current standard of care[@r6], [@r7]^)^.

The short-term evaluation of drug efficacy in DMD includes timed tests, such as 10-meter running and rising from the floor, as well as motor function evaluation by the North Star Ambulatory Assessment (NSAA)[@r8]^)^ as performed by physical therapists for ambulatory DMD patients. Other functional measures, including the 6-minute walking test, and timed tests like the 10-meter running test and the timed up and go test, are also effective evaluation tools for ambulatory DMD[@r9]^)^. Studies on medication frequency have often employed 10-meter running, 4 steps stair climbing, and muscle strength assessment as efficacy indicators[@r10]^)^. Thus, considerable evidence supports the relevance of short-term motor function assessment to evaluate PSL effectiveness.

In contrast, despite many long-term reports on the natural history of DMD[@r11], [@r12]^)^, there are few on the extended assessment of drug efficacy using motor function indicators. It has already been suggested that long-term follow-up is necessary for determining the effects of PSL[@r13]^)^. Such an understanding, if performed non-invasively, will be useful for determining future treatment policies with regard to dosage and possible side effects. Our objective was to investigate the role of long-term, non-invasive motor function evaluation by physical therapists on estimating the effect of PSL in 3 DMD cases.

PARTICIPANTS AND METHODS {#s2}
========================

The participants were 3 preschool boys with ambulatory DMD who underwent PSL treatment with the same dosage regimen starting at 1.0 mg/kg/alternate-day dose ([Table 1](#tbl_001){ref-type="table"}Table 1.Physical characteristics of participantsAt prednisolone commencementAt prednisolone dosage increaseDMD gene mutationAge (years/months)Height (cm)BMI (kg/m^2^)Serum CK (U/l)Age (years/months)Height (cm)BMI (kg/m^2^)Serum CK (U/l)Case 15/7103.716.318,7906/6108.417.634,820Nonsense mutation in exon 48Case 25/899.615.121,2806/1102.715.513,355Nonsense mutation in exon 18Case 35/7106.015.121,5106/1110.019.538,290Nonsense mutation in exon 21BMI: body mass index; CK: creatine kinase; DMD: Duchenne muscular dystrophy.). Based on declining muscle power, the doses were increased by 0.75 mg/kg/day at the discretion of the attending physician. Motor function indicators of 10-meter running time, time to rise from the floor, and NSAA score (maximum score of 34 points) were measured from starting motor function evaluation to the study end point. Furthermore, we regularly asked the participants' mothers at monthly follow-up checks for their impressions of their child's motor function after PSL commencement.

Statistical analyses were conducted using PASW Statistics software (version 24.0, SPSS, Inc., Chicago, IL, USA), and pared t-tests were employed in all analyses.

This study was approved by the institutional ethics committee of the Shinshu University School of Medicine (no. 2340 and 2804). The experiment was orally explained to the participants and their parents, all of whom consented to participation. All study procedures were carried out in accordance with the ethical standards of the 1964 Declaration of Helsinki.

RESULTS {#s3}
=======

Case 1. The patient started PSL treatment at 5 years and 7 months and dosage was increased at 6 years and 6 months. The evaluation period was set from 5.5 to 10.5 years of age. He had a comorbid diagnosis of autism spectrum disorder (ASD). Motor function testing showed a significant improvement in the mean values of all outcomes in comparisons of the period from the start of treatment to the dosage increase (Section of A; [Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Results of motor function evaluations for case 1.The solid, dashed, and dotted lines indicate the timings of prednisolone (PSL) commencement, PSL dosage increase, and the observation end point, respectively. A: Period from start of PSL treatment to dosage increase. B: Period from PSL dosage increase to observation end point. NSAA: North Star Ambulatory Assessment., [Table 2](#tbl_002){ref-type="table"}Table 2.Motor function test outcomesTestCase 1Case 2Case 3ABA vs. B^a^ABA vs. B^a^ABA vs. B^a^10-meter running (sec)4.4 ± 0.83.2 ± 0.3\*\*5.0 ± 0.44.4 ± 0.4\*4.9 ± 0.63.3 ± 0.3\*\*Rising from the floor (sec)3.4 ± 0.82.2 ± 0.4\*4.2 ± 0.63.6 ± 0.5n.s.4.1 ± 1.12.7 ± 0.4\*NSAA (/34)27.0 ± 2.132.7 ± 0.9\*\*\*25.4 ± 2.228.4 ± 2.3\*20.7 ± 1.531.4 ± 1.1\*\*\*Data are expressed as the mean ± standard deviation. ^a^pared t-test; \*p\<0.05; \*\*p\<0.01; \*\*\* p\<0.001; n.s.: not significant.A: the period from the start of treatment to the dosage increase (Case 1 and Case 2), the period from starting motor function evaluation to PSL commencement (Case 3) ; B: the period from the dosage increase to the study end point (Case 1 and Case 2), the period from the dosage increase to the study end point (Case 3). NSAA: North Star Ambulatory Assessment.) with the period from the dosage increase to the observation end point (Section of B; [Fig. 1](#fig_001){ref-type="fig"}, [Table 2](#tbl_002){ref-type="table"}). The mother's general impression was that he showed an improvement in movement and general expression during treatment.

Case 2. The patient began PSL treatment at 5 years and 8 months and dosage was increased at 6 years and 1 month. The evaluation period was set from 5.5 to 8.5 years of age. Mean results for 10-meter running and NSAA score were significantly improved over the period from the dosage increase to the study end point (Section of B; [Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Results of motor function evaluations for case 2.The solid, dashed, and dotted lines indicate the timings of prednisolone (PSL) commencement, PSL dosage increase, and the observation end point, respectively. A: Period from start of PSL treatment to dosage increase. B: Period from PSL dosage increase to observation end point. NSAA: North Star Ambulatory Assessment., [Table 2](#tbl_002){ref-type="table"}) as compared with the period from the start of treatment to the dosage increase (Section of A; [Fig. 2](#fig_002){ref-type="fig"}, [Table 2](#tbl_002){ref-type="table"}). There was no remarkable difference in time to rise from the floor (p=0.11). The mother's impression was no observable improvement after the introduction of PSL.

Case 3. The patient started PSL treatment at 5 years and 7 months and dosage was increased at 6 years and 1 month. The evaluation period was set from 3.5 to 8 years of age. He had comorbid diagnoses of attention deficit/hyperactivity disorder (ADHD) and ASD. The mean values of all outcomes during the period from starting motor function evaluation to PSL commencement (Section of A; [Fig. 3](#fig_003){ref-type="fig"}Fig.3.Results of motor function evaluations for case 3.The double, single, dashed, and dotted lines indicate the timings of motor function evaluation, prednisolone (PSL) commencement, PSL dosage increase, and the observation end point, respectively. A: Period from start of motor function evaluation to PSL commencement. B: Period from PSL dosage increase to observation end point. NSAA: North Star Ambulatory Assessment., [Table 2](#tbl_002){ref-type="table"}) and the period from the dosage increase to the study end point (Section of B; [Fig. 3](#fig_003){ref-type="fig"}, [Table 2](#tbl_002){ref-type="table"}) were significantly improved. The mother felt that there was no significant motor function improvement before and after introduction of PSL as the child had apparently displayed an elevated amount of movement even before the introduction of PSL.

DISCUSSION {#s4}
==========

It was conducted a long-term evaluation of PSL efficacy on 10-meter running time, time to rise from the floor, and NSAA score in 3 ambulatory patients with DMD who received the same dosage regimen. Apart from the time to rise from the floor for case 2, all participants' motor function outcomes improved significantly between the periods before and after a PSL increase. Thus, steroid treatment proved efficacious over 2.5--5 years after the initial administration.

In interviews with the patients' mothers on their impression of treatment outcomes, those for patients 2 and 3 differed from the objective testing results. Particularly in case 3, there was an underlying diagnosis of ADHD that could have limited the parent's ability to notice improvements in motor function. Accordingly, long-term, non-invasive evaluation by physical therapists plays an important role in objectively evaluating motor function in daily life and may assist in consultations with patients and their parents.

Regarding the use of PSL for DMD, there are currently no standard criteria for medication protocols in Japan[@r13]^)^. However, we could conclude non-invasively that the effects of PSL improved or maintained motor function over several years, which highlighted the importance of long-term monitoring of motor function.

There were several limitations to this study. First, it was performed on a small number of cases that restricted the generalizability of the results. Secondly, the evaluation period differed among participants: for cases 1 and 2, we were unable to perform longer evaluation from the start of motor function evaluation to the beginning of PSL treatment, while in case 3, there was a shorter time from the beginning of PSL administration to the dosage increase.

Future studies in larger cohorts are needed to verify our findings on long-term motor function evaluations to establish PSL commencement, increasing, and discontinuation guidelines.
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